Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Aged Garlic Extract Study

Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
EstadoTerminado
Patrocinadores
Lund University Hospital

Palabras clave

Abstracto

The primary intention of the study is to examine the effect of aged garlic extract (AGE) on the absolute change in coronary artery calcium (CAC). The second intention is to examine the effect of AGE on inflammatory biomarkers and microcirculation. It is a double blind placebo controlled study. The participants will ingest AGE during a period of one year. The CAC will be controlled by computer tomography (CT) scan; the inflammatory biomarkers through blood sample test and the microcirculation through laser speckel imagining and laser doppler before and after the one year period of AGE ingestion.

Descripción

Objectives:

Effect on coronary artery atherosclerosis / the progression of atherosclerosis Effect on inflammatory and oxidation biomarkers Cholesterol lowering effect Effect on microcirculation

Type of study:

Randomized double blind controlled trial

Number of patients: 80 patients

Duration of the study:

The patients will be studied for one year after they have entered the study. The total time of the study duration from the including date of the first patient to the analysis of the last patient entering the study estimated to be 2-3 years. An inclusion rate off 1 to 2 patients per week.

Treatment:

Dose: Treated with a placebo capsule or a capsule containing a total of AGE 2400 mg daily for 1 year (2 Kyolic capsule (600 mg) twice daily).

Methods:

Placebo-controlled double blind randomized trial to determine whether AGE can influence the rate of atherosclerosis plaque burden measured by coronary artery calcium, improve vascular function and microcirculation and favorably change biomarkers of oxidative stress.

Randomization:

The participants are assigned to AGE or placebo in a double-blinded manner, using numbered containers assigned to a computer-generated randomization chart by a nurse coordinator.

fechas

Verificado por última vez: 05/31/2019
Primero enviado: 02/25/2019
Inscripción estimada enviada: 02/27/2019
Publicado por primera vez: 02/28/2019
Última actualización enviada: 06/07/2019
Última actualización publicada: 06/10/2019
Fecha de inicio real del estudio: 11/30/2016
Fecha estimada de finalización primaria: 05/31/2019
Fecha estimada de finalización del estudio: 05/31/2019

Condición o enfermedad

Coronary Artery Disease
Microcirculation
Biomarkers

Intervención / tratamiento

Dietary Supplement: Aged Garlic Extract

Dietary Supplement: Placebo

Fase

-

Grupos de brazos

BrazoIntervención / tratamiento
Active Comparator: Aged Garlic Extract
The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
Dietary Supplement: Aged Garlic Extract
Placebo Comparator: Placebo
The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
Dietary Supplement: Placebo

Criterio de elegibilidad

Edades elegibles para estudiar 40 Years A 40 Years
Sexos elegibles para estudiarAll
Acepta voluntarios saludablessi
Criterios

Inclusion Criteria:

- CAC score >10

- Framingham risk score (10 % or above)

- Subjects are required to be on stable concomitant medications for at least 12 weeks prior to randomization

- Subjects with diabetic must have HbA1C < 8.0, and stable HbA1C level variation range within 0.5% for three months.

Exclusion Criteria:

- Hypersensitivity to AGE therapy,

- Unstable medical, psychiatric, or substance abuse disorder that may interfere with continuation in the study,

- Weight ≥325 pounds,

- Bleeding disorder,

- History of myocardial infarction,

- Stroke

- Life-threatening arrhythmia within prior 6 months,

- Resting hypotension (systolic < 90 mmHg) or hypertension (resting blood pressure >170/110)

- Heart failure NYHA class III or IV,

- History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy

- Serum creatinine >1.4 mg/dl

- Triglycerides > 400 at baseline visit

- Diabetic subjects with HbA1C > 8 %,

- Drug or alcohol abuse

- Conditions interfering with accurate assessment of coronary calcification (metal clips, bypass patients, intracoronary stents) and drug absorption (partial ileal bypass or malabsorption syndrome).

- Current use of anticoagulants (except for antiplatelet agents)

- Chronic renal failure

- Liver failure

- Hematological or biochemical values at baseline visit outside the reference ranges considered as clinically significant.

Salir

Medidas de resultado primarias

1. Change in coronary artery calcium (CAC) score [One year]

CAC is to be defined as a plaque of at least three contiguous pixels (area 1.02 mm 2) with a density of > 130 Hounsfield units. The lesion score are to be calculated by multiplying the lesion area by a density factor derived from the maximal Hounsfield unit within this area, as described by Agatston S, Janowitz WR, Hildner FJ et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832. CAC score is measured at baseline and after one year follow-up and the difference is calculated.

Medidas de resultado secundarias

1. The changes in inflammatory biomarkers. [One Year]

Changes in C-reactive protein (CRP mg/L)

2. The changes in Interleukin-6 (IL-6) [One Year]

Changes in IL-6 (ng/L)

3. The changes in inflammatory biomarkers. [One Year]

Changes in Homocystein (µmol/L)

4. The changes in the microcirculation measured by Laser Doppler velocimetry [One Year]

Laser Doppler Flowmetry (LDF) is a non-invasive method to estimate the blood perfusion in the microcirculation. The advantage of the technique is that LDF provide a continuous or near continuous record of the microvascular blood flow. No current laser Doppler instrument can present absolute perfusion values (e.g. ml/min/100 gram tissue). Measurements are expressed as perfusion units (PU) which are arbitrary. The changes in PU will be measured.

5. Changes in Low Density Lipoprotein [One Year]

Changes of Low Density Lipoprotein (LDL) mmol/L

6. Changes in Triglycerides [One Year]

Changes of Triglycerides mmol/L.

7. Changes in Cholesterol [One Year]

Changes of cholesterol mmol/L.

8. Changes in High Density Lipoprotein [One Year]

Changes of High Density Lipoprotein(HDL) mmol/L,

9. Changes in lipid profile [One Year]

Apolipoprotein B (mmol/L)/Apolipoprotein A1 (mmol/L)

10. Changes in blood sugar [One Year]

Changes in fastening blood glucose measured as mmol/L

11. Changes in Blood pressure [One Year]

Changes of blood pressure Systolic and Diastolic presented as mmHg.

12. Changes in BMI [One Year]

Changes in BMI measured as weight (kg) and height (m) and will be combined to report BMI in kg/m^2

Únete a nuestra
página de facebook

La base de datos de hierbas medicinales más completa respaldada por la ciencia

  • Funciona en 55 idiomas
  • Curas a base de hierbas respaldadas por la ciencia
  • Reconocimiento de hierbas por imagen
  • Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
  • Leer publicaciones científicas relacionadas con su búsqueda
  • Buscar hierbas medicinales por sus efectos.
  • Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.

Google Play badgeApp Store badge